Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1050851

	registered interest
	date	29/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they intend to introduce national funding for cancer genomic testing in England; and if so, when.
	tabling member printed	Lord Warner
	uin	HL13269
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>Building on the 100,000 Genomes Project and existing genetic services, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The aims of the GMS are to:</p><p>- Provide consistent and equitable care for the country’s 55 million population;</p><p>- Operate to common national standards, specifications and protocols;</p><p>- Deliver to a single national genomic testing directory – covering use of all technologies from single gene to whole genome sequencing initially for rare disease and cancer;</p><p>- Give all patients the opportunity to participate in research, for individual benefit and to inform future care; and</p><p>- Build a national genomic knowledge base to provide real world data to inform.</p><p>Through the GMS, NHS England will be exploring how to ensure that the funding flows for cancer support equity of access to testing across the country.</p> answering member printed Baroness Blackwood of North Oxford question first answered 12/02/2019 15:54:06 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1732 label Biography information for Lord Warner

1050852

	registered interest
	date	29/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what assessment they have made of the implications for patient access to treatment for those continuing to rely on the National Tariff Payment System to fund cancer genomic tests under the Genomic Medicine Service in England.
	tabling member printed	Lord Warner
	uin	HL13270
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>Funding for cancer genomic testing is included under the National Tariff Payment System, excluding whole genome sequencing which NHS England is funding nationally, and is included within the healthcare resource group tariff payment for an individual patient. For example, epidermal growth factor receptor (EGFR) testing for lung cancer, along with oestrogen (positive/negative progesterone) receptor status and human epidermal growth factor receptor 2 (HER2) testing for breast cancer have been established tests within the National Health Service for a number of years.</p><p>Cancer genomic testing will continue to be funded by the National Tariff Payment System and the National Genomic Test Directory outlines the cancer genomic tests which will be delivered by the NHS in England.</p> answering member printed Baroness Blackwood of North Oxford question first answered 12/02/2019 15:54:47 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	1732 label Biography information for Lord Warner

1050853

	registered interest
	date	29/01/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what steps they are taking, or plan to take, to mitigate the possibility of variation in patient access to cancer genomic testing in England resulting from Clinical Commissioning Group decision-making.
	tabling member printed	Lord Warner
	uin	HL13271
	answer	answer is ministerial correction date of answer 12/02/2019 answer text <p>The <em>Annual Report of the Chief Medical Officer 2016: Generation Genome</em>, made clear that in order to achieve equitable access to genomic testing the National Health Service will need to implement a first-class genomic medicine service that is scalable, future proof and delivers value for money. The report also noted the work undertaken as part of the 100,000 Genomes Project. A copy of the report is attached.</p><p>Therefore, NHS England announced in October 2018 that over the next 18 months work to mobilise the NHS Genomic Medicine Service (GMS) would get underway. The aims of the GMS are to:</p><p>- Provide consistent and equitable care for the country’s 55 million population;</p><p>- Operate to common national standards, specifications and protocols;</p><p>- Deliver to a single national genomic testing directory – covering use of all technologies from single gene to whole genome sequencing initially for rare disease and cancer;</p><p>- Give all patients the opportunity to participate in research (for individual benefit and to inform future care); and</p><p>- Build a national genomic knowledge base to provide real world data to inform.</p><p>A key element of the GMS is the National Genomic Test Directory which outlines the entire repertoire of genomic tests for cancer and rare and inherited disease – from Whole Genomic Sequencing to panel tests, to tests for single genes and molecular markers – that are available as part of the NHS clinical service in England.</p><p>The NHS GMS will be supported by an informatics system, that is being developed in partnership with Genomics England. When fully operational the National Genomics Informatics Service will enable NHS England to monitor the number of genomic tests being carried out across the country and benchmark activity.</p> answering member printed Baroness Blackwood of North Oxford question first answered 12/02/2019 16:06:53 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name HL13271 - Lord Warner - CMO_annual_report_generation_genome.pdf title CMO Annual Report 2016 Generation Genome
	tabling member	1732 label Biography information for Lord Warner

1147651

	registered interest
	date	01/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to increase the uptake of checks for breast, bowel, and cervical diseases; and whether they intend to publish guidance to NHS trusts in England about ways in which such trusts can increase the uptake of such checks.
	tabling member printed	Baroness Redfern
	uin	HL17977
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>NHS England is committed to improving the uptake of national cancer screening programmes, for breast, bowel, and cervical cancer.</p><p>In January, NHS England published its Long Term Plan, which outlined its ambition to deliver improvements in the uptake of national cancer screening programmes. To support this process, NHS England has developed improving uptake action plans, which can be used by providers and the wider health system, to improve the performance of screening programmes.</p><p>The uptake action plans include proposals for reviewing and extending appointment hours (for example for breast cancer screening) and using data to inform strategies for improving uptake in those populations of greatest need. These plans are already available to commissioning teams and will be updated and reissued throughout the year.</p><p>National Health Service regions are currently developing implementation plans to deliver on these commitments. To provide robust oversight and assurance of delivery, NHS England has established national programme boards for each cancer screening programme area.</p><p>In addition, we expect the Sir Mike Richards’ Review of Screening report, due to be published soon, to identify additional opportunities to improve the uptake of breast, bowel, and cervical screening.</p><p>Further, Public Health England has been running ‘Be Clear on Cancer’ campaigns since 2011. These are designed to raise the public’s awareness of specific cancer symptoms; encourage people with those symptoms to go to the doctor; and diagnose cancer at an earlier stage, and therefore make it more treatable, and thereby improve cancer survival rates.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:40:48 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4551 label Biography information for Baroness Redfern

1147652

	registered interest
	date	01/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what consideration they have given to using (1) smartphone bookings, (2) text reminders, (3) evening appointments, and (4) accessible locations, for cancer screening appointments; and what assessment, if any, they have made of whether such measures would increase (a) the uptake of such screenings, and (b) early diagnosis.
	tabling member printed	Baroness Redfern
	uin	HL17978
	answer	answer is ministerial correction date of answer 08/10/2019 answer text <p>NHS England recognises the importance of delivering public health services, including screening, which people find easy to access. This is why the NHS Long Term Plan and detailed improvement actions are about ensuring services are easy and convenient for people to use in order to deliver the Long Term Plan ambition on cancer to see 55,000 more people surviving cancer for five years in England each year from 2028.</p><p>The actions plans include real-world case studies which have demonstrated improvements in local areas. These case studies sit alongside widely published evidence which has been proven to deliver improvements in uptake. We expect these actions to have a positive impact on the uptake of screening.</p><p>Sir Mike Richards’ Review of Screening report is due to be published shortly which will identify additional opportunities to improve the uptake of breast, bowel, and cervical screening. In addition, NHSX is looking at possible improvements to screening IT systems, which should support the delivery of cancer screening programmes.</p> answering member printed Baroness Blackwood of North Oxford question first answered 08/10/2019 16:41:24 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4551 label Biography information for Baroness Redfern

1625809

	registered interest
	date	03/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what is the national target time for (1) analysis, and (2) assessment, of biopsy results for patients being treated for cancer-related conditions; and what assessment they have made of whether the Royal Berkshire Hospital in Reading is meeting these.
	tabling member printed	Lord Campbell-Savours
	uin	HL7619
	answer	answer is ministerial correction date of answer 23/05/2023 answer text <p>There is no national target time for analysis and assessment of biopsy results for patients being treated for cancer related conditions.</p> answering member printed Lord Markham question first answered 23/05/2023 14:26:44 answering member 4948 label Biography information for Lord Markham
	tabling member	499 label Biography information for Lord Campbell-Savours

1625810

	registered interest
	date	03/05/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what assessment they have made of the impact of a delay of seven weeks for the (1) analysis, and (2) assessment, of stage 3 cancer biopsy results on patients potentially under treatment for cancer.
	tabling member printed	Lord Campbell-Savours
	uin	HL7620
	answer	answer is ministerial correction date of answer 22/05/2023 answer text <p>No assessment has been made by the Department of Health and Social Care.</p> answering member printed Lord Markham question first answered 22/05/2023 16:42:17 answering member 4948 label Biography information for Lord Markham
	tabling member	499 label Biography information for Lord Campbell-Savours

1684980

	registered interest
	date	24/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government to what extent they have evaluated in the NHS-Galleri research trial the possibility that patients with small tumours will not be readily detected when circulating tumour DNA is used for diagnosis, leading to poor utility for cancer screening.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1891
	answer	answer is ministerial correction date of answer 30/01/2024 answer text <p>The Department has not made any formal evaluations, as the NHS-Galleri research trial is currently still ongoing. The trial is planned to conclude in 2025 with interim results expected during 2024, and final results anticipated in 2026.</p> answering member printed Lord Markham question first answered 30/01/2024 11:36:37 answering member 4948 label Biography information for Lord Markham
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1685690

	registered interest
	date	29/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask His Majesty's Government what oversight they are exercising over the NHS-Galleri trial.
	tabling member printed	Lord Hunt of Kings Heath
	uin	HL1993
	answer	answer is ministerial correction date of answer 05/02/2024 answer text <p>In 2021 the United Kingdom and devolved administrations set out their vision for the future of clinical research delivery, including for the NHS Galleri trial. Saving and Improving Lives: The Future of UK Clinical Research Delivery lays out the ambition to create a world-leading UK clinical research environment that is more efficient, more effective and more resilient, with research delivery embedded across the National Health Service. A copy of this document is attached.</p><p>The cross-sector partnerships built through the UK Clinical Research Recovery, Resilience and Growth (RRG) programme provide the strong foundations needed to succeed, drawing on expertise and support from industry, academia, charities, patients and the public, regulators, funders and the NHS. The RRG programme provides system leadership, oversight and strategic co-ordination of the work in order to implement the plans and deliver the ambitions set. It is co-ordinated by the Department and is making progress across a number of commitments.</p> answering member printed Lord Markham question first answered 05/02/2024 12:23:57 answering member 4948 label Biography information for Lord Markham attachment 1 file name The-future-of-UK-clinical-research-delivery.pdf title The Future of UK Clinical Research Delivery
	tabling member	2024 label Biography information for Lord Hunt of Kings Heath

1060784

	registered interest
	date	13/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 12 February 2019 to Question 217578 on Breast Cancer: Screening, when the updated National Genomic Test Directory for cancer is due to be published.
	tabling member constituency	Scunthorpe
	tabling member printed	Nic Dakin
	uin	220890
	answer	answer is ministerial correction date of answer 18/02/2019 answer text <p>The updated National Genomic Test Directory for cancer will be issued by the end of February 2019.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 18/02/2019 17:12:44 answering member 4067 label Biography information for Steve Brine
	tabling member	4056 label Biography information for Nic Dakin